EurekaMag.com logo
+ Translate

Novel benzoxazole inhibitors of mPGES-1


, : Novel benzoxazole inhibitors of mPGES-1. Bioorganic & Medicinal Chemistry Letters 23(3): 907-911

A novel series of potent benzoxazole mPGES-1 inhibitors has been derived from a hit from a high throughput screen. Compound 37 displays mPGES-1 inhibition in an enzyme assay (0.018 μM) and PGE-2 inhibition in a cell-based assay (0.034 μM). It demonstrates 500- and 2500-fold selectivity for mPGES-1 over COX-2 and 6-keto PGF-1α, respectively. In vivo PK studies in dogs demonstrate 55% oral bioavailability and an 7 h half-life.

(PDF same-day service: $19.90)

Accession: 054669412

PMID: 23266122

DOI: 10.1016/j.bmcl.2012.10.040

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Liedtke, A.J.; Keck, P.R.W.E.F.; Lehmann, F.; Koeberle, A.; Werz, O.; Laufer, S.A., 2009: Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). We synthesized and evaluated inhibitors for the microsomal prostaglandin E2 synthase-1 (mPGES-1), based on the arylpyrrolizine scaffold. In a cell free mPGES-1 assay several "sulfonimides" exceeded our lead ML3000 (3) in potency. The mos...

Iranshahi, M.; Chini, M.Giovanna.; Masullo, M.; Sahebkar, A.; Javidnia, A.; Chitsazian Yazdi, M.; Pergola, C.; Koeberle, A.; Werz, O.; Pizza, C.; Terracciano, S.; Piacente, S.; Bifulco, G., 2016: Can Small Chemical Modifications of Natural Pan-inhibitors Modulate the Biological Selectivity? The Case of Curcumin Prenylated Derivatives Acting as HDAC or mPGES-1 Inhibitors. Curcumin, or diferuloylmethane, a polyphenolic molecule isolated from the rhizome of Curcuma longa, is reported to modulate multiple molecular targets involved in cancer and inflammatory processes. On the basis of its pan-inhibitory characteristic...

Mattila, S.; Tuominen, H.; Koivukangas, J.; Stenbäck, F., 2009: The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas. Prostaglandin E2 has been connected to processes promoting tumor growth in several human malignancies including gliomas. The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES convert PGH2 into prostaglandin E2. The inhibition of their f...

Giannico, G.; Mendez, M.; LaPointe, M.C., 2004: Regulation of the membrane-localized prostaglandin E synthases mPGES-1 and mPGES-2 in cardiac myocytes and fibroblasts. The proinflammatory mediator cyclooxygenase (COX)-2 and its product PGE2 are induced in the ischemic heart, contributing to inflammatory cell infiltration, fibroblast proliferation, and cardiac hypertrophy. PGE2 synthesis coupled to COX-2 involves...

Radi, Z.A.; Ostroski, R., 2007: Pulmonary and cardiorenal cyclooxygenase-1 (COX-1), -2 (COX-2), and microsomal prostaglandin E synthase-1 (mPGES-1) and -2 (mPGES-2) expression in a hypertension model. Hypertensive mice that express the human renin and angiotensinogen genes are used as a model for human hypertension because they develop hypertension secondary to increased renin-angiotensin system activity. Our study investigated the cellular lo...

Radi, Z., A.; Ostroski, R., 2007: Pulmonary and cardiorenal cyclooxygenase-1 (COX-1),-2 (COX-2), and microsomal prostaglandin E synthase-1 (mPGES-1) and-2 (mPGES-2) expression in a hypertension model. Hypertensive mice that express the human renin and angiotensinogen genes are used as a model for human hypertension because they develop hypertension secondary to increased renin-angiotensin system activity. Our study investigated the cellular lo...

Leclerc, P.; Idborg, H.; Spahiu, L.; Larsson, C.; Nekhotiaeva, N.; Wannberg, J.; Stenberg, P.; Korotkova, M.; Jakobsson, P-Johan., 2014: Characterization of a human and murine mPGES-1 inhibitor and comparison to mPGES-1 genetic deletion in mouse models of inflammation. Microsomal prostaglandin E synthase-1 (mPGES-1) inhibition has been suggested as an alternative to cyclooxygenase (COX) inhibition in the treatment of pain and inflammation. We characterized a selective inhibitor of mPGES-1 activity (compound III)...

Gudis, K.; Tatsuguchi, A.; Wada, K.; Futagami, S.; Nagata, K.; Hiratsuka, T.; Shinji, Y.; Miyake, K.; Tsukui, T.; Fukuda, Y.; Sakamoto, C., 2004: Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue. Recently, three different prostaglandin E2 synthases have been identified: microsomal prostaglandin E synthase (mPGES)-1, cytosolic PGES (cPGES), and mPGES-2; however, their role and connection to cyclooxygenase (COX)-2 in the gastric ulcer repair...

Chang, H-Hua.; Meuillet, E.J., 2012: Identification and development of mPGES-1 inhibitors: where we are at?. Microsomal prostaglandin E synthase-1 (mPGES-1) is the terminal synthase responsible for the synthesis of the pro-tumorigenic prostaglandin E(2) (PGE(2)). mPGES-1 is overexpressed in a wide variety of cancers. Since its discovery in 1997 by Bengt...

Park, S-Jun.; Han, S-Gu.; Ahsan, H.Muhammad.; Lee, K.; Lee, J.Yeol.; Shin, J-Sun.; Lee, K-Tae.; Kang, N-Suk.; Yu, Y.Gyu., 2013: Identification of novel mPGES-1 inhibitors through screening of a chemical library. Human microsomal prostaglandin E synthase-1 (mPGES-1) is an emerging drug target for inflammatory disorders and cancer suppression. Therefore, it is crucially important to discover mPGES-1 inhibitors with novel structural scaffolds for the develop...